Michael Lovett
Directeur/Membre du Conseil chez Biosceptre (Aust) Pty Ltd.
Profil
Michael Lovett currently works at Biosceptre (Aust) Pty Ltd., as Non-Executive Director and Biosceptre International Ltd., as Non-Executive Director.
Postes actifs de Michael Lovett
Sociétés | Poste | Début |
---|---|---|
Biosceptre (Aust) Pty Ltd.
Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Directeur/Membre du Conseil | - |
Biosceptre International Ltd.
Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Biosceptre (Aust) Pty Ltd.
Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Health Technology |
Biosceptre International Ltd.
Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Health Technology |